BACKGROUND: Sustained hypertension induces renovascular remodelling by altering extracellular matrix (ECM) components. Matrix metalloproteinases (MMPs) are Zn-dependent enzymes that regulate ECM turnover in concert with their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Increased MMP-2 and MMP-9 have been implicated in hypertensive complications; however, the contribution of individual MMPs/TIMPs in renal remodelling has not been fully elucidated. The purpose of this study was to determine the effect of TIMP2 deficiency and thus MMP-2 on angiotensin-II (Ang-II) induced renal remodelling. METHOD: C57BL/6J (wild-type) and TIMP2 knockout mice were infused with Ang-II at 250 ng/kg per min for 4 weeks. Blood pressure was measured weekly and end-point laser Doppler flowmetry was done to assess cortical blood flow. Immunohistochemical staining was performed for collagen and elastin analyses. The activity of MMP-9 and MMP-2 was determined by Gelatin zymography. RESULTS: Ang-II induced similar elevation in mean blood pressure in TIMP2 and wild-type mice. In TIMP2 mice, Ang-II treatment was associated with a greater reduction in renal cortical blood flow and barium angiography demonstrated decreased vascular density compared with Ang-II treated wild-type mice. Peri-glomerular and vascular collagen deposition was increased and elastin content was decreased causing increased wall-to-lumen ratio in TIMP2 mice compared with wild-type mice receiving Ang-II. Ang-II increased the expression and activity of MMP-9 predominantly in TIMP2 mice than in wild-type mice. CONCLUSION: These results suggest that TIMP2 deficiency exacerbates renovascular remodelling in agonist-induced hypertension by a mechanism that may, in part, be attributed to increased activity of MMP-9.
BACKGROUND: Sustained hypertension induces renovascular remodelling by altering extracellular matrix (ECM) components. Matrix metalloproteinases (MMPs) are Zn-dependent enzymes that regulate ECM turnover in concert with their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Increased MMP-2 and MMP-9 have been implicated in hypertensive complications; however, the contribution of individual MMPs/TIMPs in renal remodelling has not been fully elucidated. The purpose of this study was to determine the effect of TIMP2deficiency and thus MMP-2 on angiotensin-II (Ang-II) induced renal remodelling. METHOD: C57BL/6J (wild-type) and TIMP2 knockout mice were infused with Ang-II at 250 ng/kg per min for 4 weeks. Blood pressure was measured weekly and end-point laser Doppler flowmetry was done to assess cortical blood flow. Immunohistochemical staining was performed for collagen and elastin analyses. The activity of MMP-9 and MMP-2 was determined by Gelatin zymography. RESULTS:Ang-II induced similar elevation in mean blood pressure in TIMP2 and wild-type mice. In TIMP2mice, Ang-II treatment was associated with a greater reduction in renal cortical blood flow and barium angiography demonstrated decreased vascular density compared with Ang-II treated wild-type mice. Peri-glomerular and vascular collagen deposition was increased and elastin content was decreased causing increased wall-to-lumen ratio in TIMP2mice compared with wild-type mice receiving Ang-II. Ang-II increased the expression and activity of MMP-9 predominantly in TIMP2mice than in wild-type mice. CONCLUSION: These results suggest that TIMP2deficiency exacerbates renovascular remodelling in agonist-induced hypertension by a mechanism that may, in part, be attributed to increased activity of MMP-9.
Authors: Mingyi Wang; Jing Zhang; Gaia Spinetti; Li-Qun Jiang; Robert Monticone; Di Zhao; Linda Cheng; Melissa Krawczyk; Mark Talan; Gianfranco Pintus; Edward G Lakatta Journal: Am J Pathol Date: 2005-11 Impact factor: 4.307
Authors: Edward R Smith; Laurie A Tomlinson; Martin L Ford; Lawrence P McMahon; Chakravarthi Rajkumar; Stephen G Holt Journal: Hypertension Date: 2012-03-12 Impact factor: 10.190
Authors: Vanessa Fontana; Pamela S Silva; Vanessa A Belo; Raquel C Antonio; Carla S Ceron; Celso Biagi; Raquel F Gerlach; Jose E Tanus-Santos Journal: Basic Clin Pharmacol Toxicol Date: 2011-04-04 Impact factor: 4.080
Authors: C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos Journal: EMBO J Date: 1998-09-01 Impact factor: 11.598
Authors: S Kim; K Ohta; A Hamaguchi; T Omura; T Yukimura; K Miura; Y Inada; T Wada; Y Ishimura; F Chatani Journal: Kidney Int Date: 1994-11 Impact factor: 10.612
Authors: Madhu V Singh; Michael Z Cicha; Sarah Nunez; David K Meyerholz; Mark W Chapleau; François M Abboud Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-22 Impact factor: 4.733